Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Insulin-Dependent Diabetes Mellitus 1 Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References

NCT01415544
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
Interventions
Not listed
Lead sponsor
InLight Solutions
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

NCT02218619
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tauroursodeoxycholic Acid (TUDCA), Sugar Pill (placebo)
Drug
Lead sponsor
Robin Goland, MD
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

NCT03170544
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 28, 2026, 11:29 AM EDT
Recruiting Not applicable Interventional

A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes

NCT06752928
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Dexcom G7 rtCGM, Capillary Blood glucose Testing (POC)
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Sleep Promotion to Improve Diabetes Management in Adolescents With T1D

NCT02786953
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sleep Promotion
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 28, 2026, 11:29 AM EDT
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Not applicable Interventional

InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy

NCT06411548
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
InsuLearn
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Recruiting Not applicable Interventional

Insulin Delivery With Self-Adjusting Closed-Loop and Behavioral Glycemic Control Enhanced by Prediction

NCT07507708
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Automated Insulin Delivery (AID), AIDANET + Fully Closed Loop (FCL), AIDANET + Anticipatory Closed Loop (ACL)
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 1 Interventional

Rilonacept in Diabetes Mellitus Type 1: Safety Study

NCT00962026
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rilonacept
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Role of Exenatide in Type 1 Diabetes

NCT00456300
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop MPC vs Control IQ

NCT05799781
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MPC closed-loop system, t:slim X2 pump with Dexcom G6 CGM and Control IQ
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Recruiting No phase listed Observational

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

NCT07676565
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Newport Beach, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

NCT04740307
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Duarte, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

NCT01900834
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
14 Years to 40 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 28, 2026, 11:29 AM EDT
Completed No phase listed Observational Results available

I-Tracking Neurodegeneration in Early Wolfram Syndrome

NCT03951298
View directory record Official record
Conditions
Wolfram Syndrome
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics

NCT00607230
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
BCG, Saline
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 28, 2026, 11:29 AM EDT
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting

NCT03241212
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years to 21 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Insulin Delivery Using Microneedles in Type 1 Diabetes

NCT00837512
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Microneedle, Subcutaneous insulin catheter
Device
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Diabetes

NCT03436992
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant Cocktail, Resveratrol, Placebo
Dietary Supplement · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 40 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 28, 2026, 11:29 AM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 28, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus

NCT01792284
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY2605541, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Concord, California • Escondido, California • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 28, 2026, 11:29 AM EDT